FTY720 - mechanism of action of a novel immune modulator

The novel immune modulator Fingolimod (FTY720) opens a new chapter for the therapy of autoimmune diseases like multiple sclerosis and for the prevention of allograft rejection. Scientists and physicians, experts in the field of immunosuppression, report about the initial discovery of FTY720 by T. Fujita in Japan followed by a decade of world wide research activities to uncover its unique mechanism of action. The lymphocyte recirculation modulated by FTY720 can be regarded as a novel concept to attenuate the immune system. Moreover, FTY720 as a molecular tool, revealed new insights in the regulation of the immune response and a better understanding of immunity. FTY720 binds to sphingosine receptors, which are recognized as an important molecular target for further new drugs. For professionals, students and others interested, this textbook provides a comprehensive summary about an exciting topic of recent immune-pharmacological research.